antiviral and associated therapy - all results

Treatment	Number of studies	clinical deterioration	clinical improvement	deaths	viral clearance
chloroquine and derivatives	45 studies[1]	1.04 [0.80 ; 1.35], 6 RCTs, I2=0% inconclusive result	1.07 [0.83 ; 1.39], 3 RCTs, I2=0% inconclusive result	1.07 [0.97 ; 1.18], 30 RCTs, I2=0% inconclusive result	0.97 [0.73 ; 1.29], 3 RCTs, I2=0% inconclusive result
ivermectin	21 studies[2]	0.66 [0.32 ; 1.34], 4 RCTs, I2=69% inconclusive result	1.67 [1.05 ; 2.66], 3 RCTs, I2=0% moderate degree of certainty	0.66 [0.44 ; 1.00], 10 RCTs, I2=0% inconclusive result	0.93 [0.78 ; 1.10], 2 RCTs, I2=0% inconclusive result
favipiravir	19 studies[3]	-	1.65 [1.28 ; 2.13], 5 RCTs, I2=0% moderate degree of certainty	1.13 [0.76 ; 1.70], 7 RCTs, I2=0% inconclusive result	1.45 [0.98 ; 2.13], 8 RCTs, I2=64% inconclusive result
remdesivir	10 studies[4]	0.95 [0.55 ; 1.64], 1 RCT, I2=0% inconclusive result	1.17 [0.92 ; 1.49], 5 RCTs, I2=71% demonstrated inconclusive result	0.83 [0.67 ; 1.03], 7 RCTs, I2=15% inconclusive result	-
hydroxychloroquine plus macrolides	9 studies[5]	0.99 [0.57 ; 1.72], 1 RCT, I2=0% inconclusive result	0.81 [0.54 ; 1.22], 1 RCT, I2=0% inconclusive result	0.63 [0.20 ; 2.03], 3 RCTs, I2=0% inconclusive result	-
azithromycin	8 studies[6]	1.07 [0.63 ; 1.82], 1 RCT, I2=0% inconclusive result	0.76 [0.56 ; 1.04], 2 RCTs, I2=0% inconclusive result	0.99 [0.79 ; 1.26], 5 RCTs, I2=28% inconclusive result	715.00 [12.94 ; 39513.71], 1 study, I2=0% certainty unassessable
lopinavir/ritonavir	8 studies[7]	3.69 [0.37 ; 36.57], 1 RCT, I2=0% inconclusive result	1.72 [0.98 ; 3.01], 3 RCTs, I2=64% inconclusive result	0.99 [0.89 ; 1.09], 8 RCTs, I2=0% inconclusive result	1.95 [0.73 ; 5.23], 3 RCTs, I2=72% demonstrated inconclusive result
sofosbuvir and daclatasvir	5 studies[8]	-	-	1.11 [0.87 ; 1.40], 4 RCTs, I2=0% inconclusive result	-
umifenovir (arbidol)	5 studies[9]	0.86 [0.06 ; 11.36], 1 RCT, I2=0% inconclusive result	-	1.00 [0.18 ; 5.59], 2 RCTs, I2=0% inconclusive result	2.80 [0.31 ; 25.53], 1 RCT, I2=0% inconclusive result
bromhexine	3 studies[10]	0.48 [0.01 ; 27.44], 1 RCT, I2=0% inconclusive result	-	0.09 [0.00 ; 1.68], 1 RCT, I2=0% inconclusive result	-

Continued on next page

Downloaded from www.metaEvidence.org

Treatment	Number of studies	clinical deterioration	clinical improvement	deaths	viral clearance
nitazoxanide	3 studies[11]	1.02 [0.29 ; 3.58], 1 RCT, I2=0% inconclusive result	0.81 [0.52 ; 1.27], 1 RCT, I2=0% inconclusive result	1.02 [0.02 ; 51.70], 1 RCT, I2=0% inconclusive result	-
doxycycline	2 studies[12]	0.44 [0.24 ; 0.78], 2 RCTs, I2=0% moderate degree of certainty	1.89 [1.06 ; 3.38], 1 RCT, I2=0% certainty unassessable	0.39 [0.11 ; 1.42], 2 RCTs, I2=0% inconclusive result	-
sofosbuvir	2 studies[13]	-	-	-	-
sofosbuvir and ledipasvir	2 studies[14]	-	-	-	-
azvudine	1 study[15]	-	-	1.00 [0.02 ; 55.80], 1 RCT, I2=0% inconclusive result	28.50 [1.27 ; 640.66], 1 RCT, I2=0% certainty unassessable
baloxavir marboxil	1 study[16]	-	-	1.00 [0.02 ; 55.80], 1 RCT, I2=0% inconclusive result	-
darunavir cobicistat	1 study[17]	2.07 [0.06 ; 66.79], 1 RCT, I2=0% inconclusive result	-	1.00 [0.02 ; 53.89], 1 RCT, I2=0% inconclusive result	0.82 [0.36 ; 1.87], 1 RCT, I2=0% inconclusive result
Emtricitabine/tenofovir plus colchicine plus rosuvastatin	1 study[18]	-	-	0.62 [0.33 ; 1.17], 1 RCT, I2=0% inconclusive result	-
Ensitrelvir (XOCOVA)	1 study[19]	-	-	-	-
favipiravir plus interferon	1 study[20]	-	-	0.83 [0.23 ; 2.96], 1 RCT, I2=0% inconclusive result	-
Lopinavir/ritonavir plus hydroxychloroquine	1 study[21]	-	0.63 [0.37 ; 1.06], 1 RCT, I2=0% inconclusive result	0.58 [0.36 ; 0.93], 1 RCT, I2=0% certainty unassessable	-
lopinavir/ritonavir plus interferon ß-1a	1 study[22]	-	-	-	-

Continued on next page

Downloaded from www.metaEvidence.org

Treatment	Number of studies	clinical deterioration	clinical improvement	deaths	viral clearance
lopinavir/ritonavir, ribavirin and interferon beta-1b	1 study[23]	-	3.92 [1.66 ; 9.24], 1 RCT, I2=0% certainty unassessable	0.47 [0.01 ; 24.30], 1 RCT, I2=0% inconclusive result	4.37 [1.86 ; 10.25], 1 RCT, I2=0% demonstrated certainty unassessable
niclosamide	1 study[24]	-	-	1.00 [0.20 ; 5.12], 1 RCT, I2=0% inconclusive result	-
nirmatrelvir / ritonavir (Paxlovid)	1 study[25]	-	-	-	-
oseltamivir	1 study[26]	-	-	-	-
tenofovir/emtricitabine	1 study[27]	-	-	-	-
zinc	1 study[28]	-	-	0.77 [0.11 ; 5.34], 1 RCT, I2=0% inconclusive result	-

Notes

[1]FACCT Trial, 2021 (NCT04392973) ; HYDRA (Hernandez-Cardenas), 2021 (NCT04315896) ; Abd-Elsalam, 2020 (NCT04353336) ; ARCHAIC -hydroxychloroquine, 2020 (NL8490) ; CCAP-1, 2020 (NCT04345289) ; Chen, 2020 (NCT04384380) ; Chen, ChiCTR2000030054 - Chloroquine, 2020 (ChiCTR2000030054) ; ChiCTR2000030054-HCQ (Chen), 2020 (ChiCTR2000030054) ; Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 (NCT04322123) ; Duke university HCQ, 2020 (NCT04335552) ; Duke University hydroxychloroquine/azithromycine, 2020 (NCT04335552) ; Gonzalez (HCQ), 2020 (NCT04391127) ; HAHPS, 2020 (NCT04329832) ; HC-nCoV (Shanghai), 2020 (NCT04261517) ; Huang, 2020 (ChiCTR2000029542) ; HYCOVID, 2020 (NCT04325893) ; Kamran, 2020 (NCT04491994) ; NCT04333654, 2020 (NCT04333654) ; NCT04342650, 2020 (NCT04342650) ; NO COVID-19 (Lyngbakken), 2020 (NCT04316377) ; OAHU-COVID19, 2020 (NCT04345692) ; ORCHID, 2020 (NCT04332991) ; PROTECT A, 2020 (NCT04338698) ; PROTECT B, 2020 (NCT04338698) ; RECOVERY, 2020 (NCT04381936) ; REMAP-CAP-HCQ, 2020 (NCT02735707) ; SOLIDARITY (WHO study) HCQ, 2020 (NCT04315948) ; Tang, 2020 (ChiCTR2000029868) ; TEACH, 2020 (NCT04369742) ; Zhaowei Chen, 2020 (ChiCTR2000029559) ; Arshad (HCQ), 2020 () ; Belgian Collaborative Group on COVID-19, 2020 () ; Chen$_chloroquine, 2020(); Geleris, 2020(); Huc$

[2]I-TECH (Lim), 2022 (NCT04920942) ; Abd-Elsalam, 2021 (NCT04403555) ; Babalola, 2021 () ; Bukhari, 2021 (NCT04392713) ; Galan, 2021 (RBR-8h7q82) ; Kirti, 2021 (CTRI/2020/08/027225) ; RIVET-COV (Mohan) (12mg and 24mg), 2021 (CTRI/2020/06/026001) ; Ahmed, 2020 () ; Chaccour, 2020 (NCT04390022) ; Chachar, 2020 (NCT04739410) ; Gonzalez (IVER), 2020 (NCT04391127) ; Hashim A, 2020 (NCT04591600) ; Krolewiecki, 2020 (NCT004381884) ; NCT04523831 (Mahmud), 2020 (NCT04523831) ; Okumuş, 2020 (NCT04646109) ; Shahbaznejad, 2020 (IRCT20111224008507N3) ; Glorial F, 2020 (NCT04343092) ; Camprubi, 2020 () ; Espitia-Hernandez, 2020 () ; Spoorthi, 2020 ()

[3]FACCT Trial, 2021 (NCT04392973) ; Holubar M, 2021 (NCT04346628) ; Shenoy S, 2021 (NCT04529499) ; Shinkai, 2021 (JapicCTI-205238) ; Solaymani-Dodaran, 2021 (IRCT20200318046812N1) ; AVIFAVIR, 2020 (NCT04434248) ; Chang Chen et al., 2020 (ChiCTR2000030254) ; Dabbous HM, 2020 (NCT04349241) ; jRCTs041190120, 2020 (jRCTs041190120) ; Lou (FAVIPIRAVIR), 2020 (ChiCTR2000029544) ; NCT04310228-FAVI (Zhao), 2020 (ChiCTR2000030894) ; NCT04542694, 2020 (NCT04542694) ; Ruzhentsova T, 2020 (NCT04501783) ; Udwadia, 2020 (CTRI/2020/05/025114) ; Calik, 2020 () ; Kocayigit H, 2020 () ; Cai -FAVIPIRAVIR, 2020 (ChiCTR2000029600)

[4]Andreas (NOR-Solidarity), 2021 (NCT04321616) ; DisCoVeRy (remdesivir), 2021 (NCT04315948) ; Mahajan, 2021 () ; Norwegian NOR study (remdesivir), 2021 (NCT04321616) ; CAP-China (Wang et al.), 2020 (NCT04257656) ; GS-US-540-5773 (Goldman), 2020 (NCT04292899) ; GS-US-540-5774, 10 days, 2020 (NCT04292730) ; GS-US-540-5774, 5 days, 2020 (NCT04292730) ; NIH NIAID ACTT-1, 2020

Downloaded from www.metaEvidence.org

(NCT04280705) ; SOLIDARITY (remdesivir), 2020 (NCT04315948)

[5]ProPAC-COVID, 2021 (NCT04322396) ; Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 (NCT04322123) ; Duke university HCQ-AZI, 2020 (NCT04335552) ; Arshad (HCQ AZ), 2020 () ; Davido, 2020 (NCT04453501) ; Lagier, 2020 () ; Magagnoli (HC AZ), 2020 () ; Rosenberg, 2020 () ; Sbidian (HCQ plus AZI), 2020 ()

[6]Rashad A (AZI vs SoC), 2021 () ; COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 (NCT04322123) ; COALITION II Covid-19 Brazil (Furtado), 2020 (NCT04321278) ; RECOVERY (AZI, Horby), 2020 (NCT04381936) ; Sekhavati, 2020 (IRCT20200415047092N1) ; Rodriguez-Molinero, 2020 () ; Rosenberg, 2020 () ; Espitia-Hernandez, 2020 ()

[7]Ader (lopinavir/ritonavir), 2021 (NCT04315948) ; Cao, 2020 (ChiCTR2000029308) ; ELACOI (lopinavir/ritonavir), 2020 (NCT04252885) ; Nojomi, 2020 (IRCT20180725040596N2) ; RECOVERY, 2020 (NCT04381936) ; REMAP-CAP (lopinavir/ritonavir only), 2020 (NCT02735707) ; SOLIDARITY (lopi/rito), 2020 (NCT04315948) ; Chen$_{lopi_rito,2020()}$

[8]Mobarak (DISCOVER), 2021 (IRCT20200624047908N1) ; Mobarak S (DISCOVER), 2021 (IRCT20200624047908N) ; Sadeghi , 2020 (IRCT20200128046294N2) ; Yakoot, 2020 (DRKS00022203) ; Eslami, 2020 (IRCT20200324046850N2)

[9]ELACOI (Lopinavir/ritonavir), 2020 (NCT04252885) ; ELACOI (Standard of care), 2020 (NCT04252885) ; Nojomi, 2020 (IRCT20180725040596N2) ; Yethindra, 2020 (None) ; Chen$_{arbidol,2020()}$

[10]Tolouian, 2021 () ; Ansarin, 2020 (IRCT202003117046797N) ; Li T, 2020 (NCT04273763)

[11]Fontanesi, 2021 (NCT04348409) ; Silva, 2021 (NCT04463264) ; Rocco, 2020 (NCT04552483)

[12]Spoorthi, 2020 ()

[13]Alavi-moghaddam, 2021 (IRCT20200328046882N1) ; Sali, 2021 ()

[14]Elgohary, 2021 (NCT04530422) ; Nourian A, 2020 (IRCT20100228003449)

[15]Ren, 2020 (ChiCTR2000029853)

[16]Lou Y, 2020 (ChiCTR2000029544)

[17]Jun C, 2020 (NCT04252274)

[18]Gaitan-Duarte (Rosuvastatin plus colchicine plus emtricitabine/tenofovir), 2021 (NCT04359095)

[19]Mukae - Phase 2a, 2022 (jRCT2031210350)

[20]Khamis, 2020 ()

[21]REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 (NCT02735707)

[22]Ader (lopinavir/ritonavir plus interferon), 2021 (NCT04315948)

[23]Hung et al., 2020 (NCT04276688)

[24]Abdulamir, 2021 (NCT04753619)

[25]EPIC-SR, 0 (NCT05011513)

[26]Chen$_{oseltamivir,2020()}$

[27]Gaitan-Duarte (Emtricitabine/Tenofovir), 2021 (NCT04359095)

[28]Patel, 2021 (ACTRN12620000454976)

Downloaded from www.metaEvidence.org